Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Vanda Pharmaceuticals (VNDA) over the last 11 years, with Q4 2025 value amounting to $103.2 million.

  • Vanda Pharmaceuticals' Tax Provisions rose 661274.45% to $103.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $81.8 million, marking a year-over-year increase of 213388.02%. This contributed to the annual value of $81.8 million for FY2025, which is 213499.13% up from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Tax Provisions is $103.2 million, which was up 661274.45% from -$5.8 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Tax Provisions peaked at $103.2 million during Q4 2025, and registered a low of -$7.9 million during Q1 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Tax Provisions averaged around $4.8 million, with its median value being $915000.0 (2023).
  • Over the last 5 years, Vanda Pharmaceuticals' Tax Provisions had its largest YoY gain of 661274.45% in 2025, and its largest YoY loss of 142509.65% in 2025.
  • Vanda Pharmaceuticals' Tax Provisions (Quarter) stood at $1.5 million in 2021, then skyrocketed by 80.22% to $2.7 million in 2022, then tumbled by 73.21% to $730000.0 in 2023, then tumbled by 317.12% to -$1.6 million in 2024, then soared by 6612.74% to $103.2 million in 2025.
  • Its last three reported values are $103.2 million in Q4 2025, -$5.8 million for Q3 2025, and -$7.7 million during Q2 2025.